2024
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
Patel A, Yoon J, Johnston H, Davidson M, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Gross I, Dean R, Kassner J, Viswabandya A, Madero-Marroquin R, Rampal R, Murthy S, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Cursio J, Odenike O. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Advances 2024, 8: 3468-3477. PMID: 38739724, PMCID: PMC11260843, DOI: 10.1182/bloodadvances.2024012880.Peer-Reviewed Original ResearchAcute myeloid leukemiaOutcomes of patientsMyeloproliferative neoplasmsMPN-AP/BPAllo-HCTMedian OSIntensive chemotherapyOverall survivalEuropean LeukemiaNetSurvival outcomesAllogeneic hematopoietic stem cell transplantationAssociated with poor survival outcomesHematopoietic stem cell transplantationInvestigate outcomes of patientsProgression of myeloproliferative neoplasmsMedian overall survivalStem cell transplantationFirst-line treatmentPoor survival outcomesMulti-center analysisAssociation of responseBlast-phaseMPN-BPCell transplantationAnalyzed patients
2023
Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies
Patel A, Yoon J, Johnston H, Davidson M, Viswabandya A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Dean R, Kassner J, Rampal R, Murthy S, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Cursio J, Odenike O. Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies. Blood 2023, 142: 3192. DOI: 10.1182/blood-2023-174790.Peer-Reviewed Original ResearchMedian overall survivalMorphologic leukemia-free stateAllo-HCTOutcome of ptsStem cell transplantIntensive chemotherapyBlast phaseBP diagnosisComplete responseChronic-phase myeloproliferative neoplasmsMyeloproliferative neoplasmsJAK inhibitorsPartial responseTreatment failureUnrelated donorsLonger median overall survivalMulti-center retrospective analysisAllogeneic stem cell transplantHematopoietic stem cell transplantMethods Retrospective chart reviewSecond malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Wang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.Peer-Reviewed Original ResearchConceptsSecond malignanciesAcute myeloid leukemiaOlder patientsMyelodysplastic syndromeMyeloproliferative neoplasmsHU usersHigh riskPolycythemia veraEssential thrombocythemiaRisk of SMAML/myelodysplastic syndromeClassical Philadelphia chromosome-negative myeloproliferative neoplasmsImpact of hydroxyureaRetrospective cohort studyUse of hydroxyureaPhiladelphia chromosome-negative myeloproliferative neoplasmsClassical myeloproliferative neoplasmsCumulative incidence probabilityCohort studyCytoreductive therapyPatient characteristicsMedian ageHU useMyeloid leukemiaSecondary myelofibrosis
2022
Concealed by the convenient: acquired von Willebrand syndrome in myeloproliferative neoplasm requires a thorough evaluation
Stempel JM, Podoltsev NA, Zeidan AM, Lee AI, Shallis RM. Concealed by the convenient: acquired von Willebrand syndrome in myeloproliferative neoplasm requires a thorough evaluation. Annals Of Hematology 2022, 101: 2559-2561. PMID: 35984499, DOI: 10.1007/s00277-022-04943-3.Peer-Reviewed Case Reports and Technical Notes
2021
Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis
Shallis RM, Siddon AJ, Zeidan AM. Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis. Current Hematologic Malignancy Reports 2021, 16: 276-285. PMID: 33890194, DOI: 10.1007/s11899-021-00632-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPersistent monocytosisAppropriate diagnosisMyelomonocytic leukemiaPCM1-JAK2 fusionChronic myelomonocytic leukemiaAcute myeloid leukemiaAcute myelomonocytic leukemiaNegative predictive valuePurpose of ReviewInMyelodysplastic syndromeReactive monocytosisFGFR1 rearrangementAdult onsetMyeloid leukemiaMonocytosisBCR-ABL1Predictive valueASXL1 mutationsMyeloproliferative neoplasmsDiagnostic approachCytometric analysisMarrow tissuesLeukemiaDiagnosisMonocytic differentiationEpidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Hematology/Oncology Clinics Of North America 2021, 35: 177-189. PMID: 33641862, DOI: 10.1016/j.hoc.2020.11.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map
Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews 2020, 42: 100706. PMID: 32517877, DOI: 10.1016/j.blre.2020.100706.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic myeloid leukemiaPolycythemia veraEssential thrombocythemiaMyeloproliferative neoplasmsClassical myeloproliferative neoplasmsPrimary myelofibrosisIncidence of CMLEnd Results program dataTyrosine kinase inhibitor therapyCML patient outcomesClonal myeloid disordersKinase inhibitor therapyPotential etiological roleInhibitor therapyMale genderRisk factorsPatient outcomesMyeloid leukemiaPMF patientsBetter survivalGeneral populationEtiological roleMyeloid disordersMolecular abnormalitiesEpidemiological literature
2019
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a “catch-all” term?
Shallis RM, Zeidan AM. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a “catch-all” term? Best Practice & Research Clinical Haematology 2019, 33: 101132. PMID: 32460977, DOI: 10.1016/j.beha.2019.101132.Peer-Reviewed Original ResearchConceptsMDS/MPNMyelodysplastic syndrome/myeloproliferative neoplasmMyeloproliferative neoplasmsClinicopathologic phenotypesRing sideroblasts